Immunogenicity and safety of a trivalent inactivated 2010-2011 influenza vaccine in Taiwan infants aged 6-12 months.

Autor(es): Hwang Kao-Pin; Hsu Yu-Lung; Hsieh Tsung-Hsueh; Lin Hsiao-Chuan; Yen Ting-Yu; Wei Hsiu-Mei; Lin Hung-Chih; Chen An-Chyi; Chow Julie Chi; Huang Li-Min


Resumo: This prospective study aimed to investigate the immune responses and safety of an influenza vaccine in vaccine-naïve infants aged 6-12 months, and was conducted from November 2010 to May 2011. Fifty-nine infants aged 6-12 months received two doses of trivalent inactivated influenza vaccine 4 weeks apart. Hemagglutination inhibition titers were measured 4 weeks after the two doses of study vaccine. Based on the assumption that a hemagglutination inhibition titer of 1:40 or greater against the antigen would be protective in adults, two doses of the study vaccine generated a protective immune response of 63.2% against influenza A(H1N1), 82.5% against influenza A(H3N2) and 38.6% against influenza B viruses in infants aged 6-12 months. The geometric mean fold rises against influenza type A and B viruses also met the European Medicines Agency criteria for flu vaccines. The solicited events within 7 days after vaccination were mild in intensity. No deaths or adverse events such as optic neuritis, cranial neuropathy, and brachial neuropathy or Guillain-Barre syndrome were reported. Two doses of inactivated influenza vaccine were well tolerated and induced a protective immune response against influenza in infants aged 6-12 months.


Palavras-Chave: Children, Immunogenicity, Infant, Influenza, Influenza vaccine, Safety


Imprenta: Vaccine, v. 32, n. 21, p. 2469-2473, 2014


Identificador do objeto digital: 10.1016/j.vaccine.2014.02.078


Descritores: Guillain-Barre Syndrome - Immune response ; Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Antibodies ; Guillain-Barre Syndrome - Immune response ; Guillain-Barre Syndrome - Infectious diseases ; Guillain-Barre Syndrome - Serology ; Guillain-Barre Syndrome - Viral infections ; Guillain-Barre Syndrome - Virus ; Guillain-Barre Syndrome - Vaccine ; Guillain-Barre Syndrome - Public health


Data de publicação: 2014